The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes

Journal of Pineal Research

Volumn 45, Issue 1, 2008, Pages 8-16

  Pizarro, Javier G ^a,b   Yeste Velasco, Marc ^a,b   Esparza, José Luis ^c   Verdaguer, Ester ^d   Pallàs, Mercè ^a,b   Camins, Antoni ^a,b   Folch, Jaume ^b,c,e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Apoptosis; B65; Cell cycle; Melatonin; Neuroblastoma

Indexed keywords

CYCLINE; MELATONIN; ROSCOVITINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; GENE EXPRESSION REGULATION; HORMONE ACTION; IN VITRO STUDY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOPAMINE; DOWN-REGULATION; MELATONIN; NEUROBLASTOMA; PURINES; RATS; SIGNAL TRANSDUCTION;

EID: 47249126749     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2007.00548.x     Document Type: Article

References (45)

1. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
2. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000 917 : 376 386.
3. Bondy SC, Sharman EH. Melatonin and the aging brain. Neurochem Int 2007 50 : 571 580.
4. Maldonado MD, Murillo-Cabezas F, Terron MP et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res 2007 42 : 1 11.
5. Nam E, Lee SM, Koh SE et al. Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res 2005 1046 : 90 96.
6. Feng Z, Zhang JT. Melatonin reduces amyloid beta-induced apoptosis in pheochromocytoma (PC12) cells. J Pineal Res 2004 37 : 257 266.
7. Mayo JC, Sainz RM, Tan DX et al. Melatonin and Parkinson's disease. Endocrine 2005 27 : 169 178.
8. Feng Z, Qin C, Chang Y, Zhang JT. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 2006 40 : 101 109.
9. Shiu SY. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res 2007 43 : 1 9.
10. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004 37 : 213 214.
11. Blask DE, Dauchy RT, Sauer LA et al. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 2004 25 : 951 960.
12. Sainz RM, Mayo JC, Tan DX et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005 63 : 29 43.
13. Cui P, Luo Z, Zhang H et al. Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J Pineal Res 2006 41 : 358 362.
14. Sainz RM, Mayo JC, Rodriguez C et al. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003 60 : 1407 1426.
15. Cini G, Neri B, Pacini A et al. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects. J Pineal Res 2005 39 : 12 20.
16. Garcia-Santos G, Antolin I, Herrera F et al. Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 2006 41 : 130 135.
17. Martín V, Herrera F, Carrera-Gonzalez P et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006 66 : 1081 1088.
18. Martín V, Herrera F, García-Santos G et al. Involvement of protein kinase C in melatonin's oncostatic effect in C6 glioma cells. J Pineal Res 2007 43 : 239 244.
19. Trubiani O, Recchioni R, Moroni F et al. Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res 2005 39 : 425 431.
20. Diaz-Corrales FJ, Asanuma M, Miyazaki I et al. Rotenone induces disassembly of the Golgi apparatus in the rat dopaminergic neuroblastoma B65 cell line. Neurosci Lett 2004 354 : 59 63.
21. Kulich SM, Chu CT. Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity. J Biosci 2003 28 : 83 89.
22. Chalovich EM, Zhu JH, Caltagarone J et al. Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem 2006 281 : 17870 17881.
23. Meijer L, Borgne A, Mulner O et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997 243 : 527 536.
24. Hajduch M, Havlieek L, Vesely J et al. Synthetic cyclin dependent kinase inhibitors. New generation of potent anticancer drugs. Adv Exp Med Biol 1999 457 : 341 353.
25. Sielecki TM, Boylan JF, Benfield PA et al. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 2000 43 : 1 18.
26. Yakisich JS, Boethius J, Lindblom IO et al. Inhibition of DNA synthesis in human gliomas by roscovitine. Neuroreport 1999 10 : 2563 2567.
27. Schang LM, Rosenberg A, Schaffer PA. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J Virol 2000 74 : 2107 2120.
28. David-Pfeuty T. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 1999 18 : 7409 7422.
29. Mgbonyebi OP, Russo J, Russo IH. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 1999 59 : 1903 1910.
30. Somerville L, Cory JG. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukaemia L1210 cells. Anticancer Res 2000 20 : 3347 3355.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 25 : 402 408.
32. Jiang Z, Hu J, LI X et al. Expression analyses of 27 DNA repair genes in astrocytoma by TaqMan low-density array. Neurosci Lett 2006 409 : 112 117.
33. Wesierska-Gadek J, Schmid G. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. Expert Opin Investig Drugs 2006 15 : 23 38.
34. Edamatsu H, Gau CL, Nemoto T et al. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 2000 19 : 3059 3068.
35. Hardscastle IR, Golding BT, Griffin RJ. Designing inhibitors of cyclin-dependent kinases. Annu Rev Pharmacol Toxicol 2002 42 : 325 348.
36. Jorda EG, Verdaguer E, Canudas AM et al. Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Neuropharmacology 2003 45 : 672 683.
37. Verdaguer E, Jorda EG, Canudas AM et al. Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle-related mechanism. Neurochem Int 2004 44 : 251 261.
38. Sherr CJ. Cancer cell cycles. Science 1996 274 : 1672 1677.
39. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000 60 : 3689 3695.
40. Whittaker SR, Walton MI, Garrett MD et al. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004 64 : 262 272.
41. Jiang W, Kahn SM, Tomita N et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992 52 : 2980 2983.
42. Verdaguer E, Susana Gde A, Clemens A et al. Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother 2007 61 : 390 399.
43. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signalling pathways. DNA Repair 2004 3 : 889 900.
44. Berardi P, Russell M, El-Osta A et al. Functional links between transcription, DNA repair and apoptosis. Cell Mol Life Sci 2004 61 : 2173 2180.
45. Harbour JW, Luo RX, Dei SA et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999 98 : 859 869.